Avacopan Combined with Cyclophosphamide in ANCA-Associated Vasculitis: A Safer and Effective Alternative to Prednisone Taper

Highlight

This analysis from the ADVOCATE trial subgroup evaluates avacopan versus prednisone taper in patients with ANCA-associated vasculitis (AAV) undergoing cyclophosphamide-based induction. Key findings include:
1. Comparable remission rates at 26 and 52 weeks between avacopan and prednisone taper.
2. Numerically lower relapse rates and significantly improved kidney function with avacopan.
3. Faster reduction in albuminuria and decreased glucocorticoid-related toxicity in the avacopan group.
4. Similar overall safety and serious adverse event rates in both groups.

Study Background